Glenmark Life Sciences Limited Bombay S.E.

Equities

GLS

INE03Q201024

Pharmaceuticals

Delayed Bombay S.E. 03:49:22 2024-04-26 am EDT 5-day change 1st Jan Change
810 INR +7.69% Intraday chart for Glenmark Life Sciences Limited +1.13% +23.50%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Glenmark Life Sciences Limited, Q4 2024 Earnings Call, Apr 25, 2024
Glenmark Life Sciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 CI
Glenmark Life Sciences Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI
Glenmark Life Sciences Limited Announces Resignation of Gita Nayyar as Non-Executive, Independent Director CI
Nirma Limited completed the acquisition of 75% stake in Glenmark Life Sciences Limited from Glenmark Pharmaceuticals Limited. CI
Glenmark Life Sciences Limited Announces Board Resignations, Effective March 6, 2024 CI
Nirma Limited completed the acquisition of 0.000738% stake in Glenmark Life Sciences Limited. CI
India's Glenmark Pharma posts loss for Q3 as remediation cost weighs RE
Transcript : Glenmark Life Sciences Limited, Q3 2024 Earnings Call, Jan 24, 2024
India's Glenmark Life Sciences posts Q3 profit rise; strong orderbook ahead, says CEO RE
Glenmark Life Sciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Paracetamol maker Granules India posts marginal rise in Q3 profit RE
Glenmark Life Signs Master Supply Agreement with Japanese Drugmaker for Urinary Anti-Spasmodic API MT
Glenmark Life Sciences Announces Another CDMO Deal CI
India's Glenmark Pharma posts Q2 loss on exceptional legal costs RE
Paracetamol maker Granules India's Q2 revenue rises on higher N.America demand RE
Transcript : Glenmark Life Sciences Limited, Q2 2024 Earnings Call, Oct 20, 2023
India's Glenmark Life Sciences posts Q2 profit rise on API boost RE
Glenmark Life Sciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Glenmark Life Sciences Limited Declares Interim Equity Dividend for the Financial Year 2023-24, Payable on or After October 23, 2023 CI
Indian paracetamol maker Valiant Laboratories lists at 16% premium RE
Glenmark Life Sciences Limited Approves Interim Dividend for the Financial Year 2022-23 CI
Glenmark Pharmaceuticals to Divest Majority Stake in Glenmark Life Sciences for INR56.5 Billion MT
INDIA STOCKS-Indian shares set for subdued open as Fed angst weighs RE
Glenmark Pharmaceuticals Divests 75% in GLS to Nirma CI
Chart Glenmark Life Sciences Limited
More charts
Glenmark Life Sciences Limited is an India-based company that is primarily engaged in the business of development, manufacture and marketing of active pharmaceutical ingredients (API). The Company’s product portfolio comprises of various therapeutic segments, which include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, gastrointestinal health, oncology, pain management and anti-infectives. Its products include Adapalene, Alogliptin Benzoate, Amiodarone HCl, Esomeprazole Sodium, Eszopiclone, Etoricoxib, Omeprazole, Oxcarbazepine, Zolpidem Tartrate, Zonisamide and Voriconazole. The Company’s products also include Vildagliptin, Aprepitant, Bosentan, Cilostazol, Deferasirox, Fluconazole, Ivacaftor, Pirfenidone, Riluzole, Sucralfate, Ticagrelor, Telmisartan and Umifenovir. The Company’s research and development facilities are located at Mahape, Ankleshwar and Dahej in India and manufacturing facilities are located at Ankleshwar, Dahej, Mohol and Kurkumbh.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
750.5 INR
Average target price
852 INR
Spread / Average Target
+13.52%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. GLS Stock
  4. GLS Stock
  5. News Glenmark Life Sciences Limited
  6. Glenmark Life Sciences Recommends Final Dividend for FY22